首页> 外文期刊>International Journal of Medical Sciences >Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population
【24h】

Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population

机译:日本人群中药物代谢酶CYP1A2,CYP2C9,CYP2C19,CYP2D6和CYP3A5遗传多态性的组合分析

获取原文
获取外文期刊封面目录资料

摘要

The Cytochrome P450 is the major enzyme involved in drug metabolism. CYP enzymes are responsible for the metabolism of most clinically used drugs. Individual variability in CYP activity is one important factor that contributes to drug therapy failure. We have developed a new straightforward TaqMan PCR genotyping assay to investigate the prevalence of the most common allelic variants of polymorphic CYP enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population. Moreover, we focused on the combination of each genotype for clinical treatment. The genotype analysis identified a total of 139 out of 483 genotype combinations of five genes in the 1,003 Japanese subjects. According to our results, most of subjects seemed to require dose modification during clinical treatment. In the near future, modifications should be considered based on the individual patient genotype of each treatment.
机译:细胞色素P450是参与药物代谢的主要酶。 CYP酶负责大多数临床使用的药物的代谢。 CYP活性的个体差异是导致药物治疗失败的重要因素之一。我们已经开发了一种新的简单的TaqMan PCR基因分型测定法,以研究日本人群中多态CYP酶CYP1A2,CYP2C9,CYP2C19,CYP2D6和CYP3A5的最常见等位基因变体的患病率。此外,我们集中于每种基因型的组合进行临床治疗。基因型分析确定了1,003名日本受试者中五个基因的483种基因型组合中的139种。根据我们的结果,大多数受试者似乎在临床治疗期间需要调整剂量。在不久的将来,应根据每种治疗的个体患者基因型考虑进行修改。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号